Parallel Advisors LLC Sells 1,326 Shares of Sanofi (NASDAQ:SNY)

Parallel Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY) by 15.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,425 shares of the company’s stock after selling 1,326 shares during the quarter. Parallel Advisors LLC’s holdings in Sanofi were worth $358,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in SNY. Victory Capital Management Inc. lifted its holdings in shares of Sanofi by 27.6% in the third quarter. Victory Capital Management Inc. now owns 8,669 shares of the company’s stock valued at $500,000 after purchasing an additional 1,876 shares in the last quarter. Prospera Financial Services Inc raised its position in Sanofi by 5.6% in the 3rd quarter. Prospera Financial Services Inc now owns 11,432 shares of the company’s stock valued at $659,000 after buying an additional 604 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Sanofi during the 3rd quarter valued at $8,728,000. First Horizon Advisors Inc. boosted its holdings in Sanofi by 15.6% during the 3rd quarter. First Horizon Advisors Inc. now owns 7,375 shares of the company’s stock worth $425,000 after acquiring an additional 998 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Sanofi by 4.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 147,955 shares of the company’s stock worth $8,527,000 after acquiring an additional 6,796 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SNY shares. The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday. They set a “neutral” rating and a $65.00 price target on the stock. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Down 1.5 %

Sanofi stock opened at $56.90 on Friday. The firm has a 50 day moving average price of $54.55 and a 200-day moving average price of $52.93. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a market capitalization of $144.40 billion, a P/E ratio of 22.85, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.